HIMS Hims & Hers Health, Inc.
HIMS Hims & Hers Health, Inc.
Healthcare · Drug Manufacturers - Specialty & Generic
Desk view
Market read
Scan convergence 3 scans as of 2026-10-16 3 neutral converging
POC $29.33 · VWAP $28.89 · -2.8% vs 12m avg buyer
Insiders quiet 0 buy / 0 sell · Form 4, 90d
Cluster CFO, COO + 2 others sold $2M, Sep 17–23
Coverage
9 related campaigns
HIMS Price Structure
Loading timeframes…
Peers
Every watchlist HIMS belongs to, members best 30-day change first — HIMS highlighted in place. Each pill: 30d change, 1d/7d, and a close spark over the last 30 calendar days (~21 sessions); hover for price, RSI, and the full chart.
@cultural-thesis
@peptide-economy
@consumer
@insider-universe
Decision history
1 scored call · newest first · projection
How to read this: Positive 30-day excess supports an enter call. For pass, avoid, sell, or exit calls, a positive number means the name kept rising after the call.
Hims & Hers reported Q2 after Monday's close (Aug 10): a loss of $0.40 per share — wider than consensus — against revenue up 3.8% year over year, with revenue and guidance described as stronger than expected. Coverage also flags renewed legal scrutiny from an FTC lawsuit over data sharing and billing practices.
full note →Against street estimates
How HIMS's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. EPS only.
Recent news
Headlines about HIMS from the desk's news pull — links go to the publisher. Not a desk read: the market read above is the desk's own.
pulled 8 days ago · Oct 9
- FinancialContent - Hims & Hers Health, Inc. Class A Common Stock (NYSE:HIMS) Stock Quote
- Hims & Hers Health (HIMS) Stock Price & Overview
- Hims & Hers Health, Inc. Reports Second Quarter 2026 Financial Results | Morningstar
- Hims & Hers Health, Inc. Reports Second Quarter 2026 Financial Results
- Hims Inc. - Hims & Hers Health, Inc. Reports Second Quarter 2026 Financial Results
HIMS research tape
229 dated scans, research, and events, newest first — the full record. Desk commentary and scheduled prints sit in their own panes.
Desk commentary
Authored analysis and challenge notes tied to HIMS.
Obesity/GLP-1 vertical: the next-gen trade is an AI-discovery + tools barbell, not a pure drug-developer bet